For stroke survivors with the most severe brain injuries, the question of whether aggressive intervention pays off long-term has remained stubbornly unanswered — until now. Large-core ischemic strokes, defined by extensive early infarct volume, have historically been considered poor candidates for mechanical thrombectomy, with physicians often defaulting to conservative medical management out of concern that restoring blood flow might worsen outcomes through hemorrhagic transformation.
This randomized clinical trial, published in JAMA, followed patients with large-core acute ischemic strokes through 12 months after randomization to either intra-arterial thrombectomy or medical management alone. The one-year data extend earlier short-term results, examining whether the functional advantages seen at 90 days — the standard endpoint in most stroke trials — persist or attenuate over time. Key outcomes tracked included functional independence, disability gradations on the modified Rankin Scale, mortality, and serious adverse events across both arms.
The durability of the thrombectomy benefit into the one-year window is the critical contribution here. Most endovascular stroke trials report 90-day outcomes as their primary endpoint, a convention based on the assumption that neurological recovery largely plateaus by that mark. If functional gains hold or even widen at 12 months, it reframes large-core stroke as a treatable condition rather than a near-futile one — with implications for how emergency protocols are designed and which patients are offered intervention. That said, important limitations apply: large-core designation itself varies across imaging criteria and institutions, and real-world thrombectomy access remains deeply unequal globally. This trial is unlikely to be the final word, but its longitudinal data substantially strengthen the evidence base for expanding thrombectomy eligibility criteria in a population that represents some of the highest-burden stroke cases.